Sign inCreate account

Report workspace tools

NCT03194009UNKNOWNanonymous

Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.

Sponsor

Source record

Instituto Nacional de Salud Publica, Mexico

Phase

Source record

Not Applicable (NA)

Modality

AI-normalized

small molecule

Target

AI-normalized

Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Indication / condition

AI-normalized

Diabetes Mellitus, Type 2

Intervention

Source record

Metformin, Lifestyle intervention

Source & freshness

Source record

NCT ID

NCT03194009

Original source

ClinicalTrials.gov

Source last updated

Mar 07, 2018

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03194009

Title

Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.

Sponsor

Instituto Nacional de Salud Publica, Mexico

Status

UNKNOWN

Phase

Not Applicable (NA)

Condition raw

Diabetes Mellitus, Type 2, Prediabetic State

Condition normalized

Diabetes Mellitus, Type 2, Prediabetic State

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Target normalized

Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Interventions

Metformin, Lifestyle intervention

Public preview

Source record

The PRuDENTE initiative, sponsored by the Instituto Nacional de Salud Publica in Mexico, aims to evaluate the cost-effectiveness of metformin combined with lifestyle modifications in preventing type 2 diabetes among pre-diabetic adults with obesity. Given the high prevalence of diabetes in Mexico, this study addresses a significant public health challenge and has the potential to inform national healthcare policies. If successful, the findings could lead to broader adoption of metformin as a preventive measure, impacting the pharmaceutical market for diabetes medications and lifestyle interventions. The study's outcomes may also attract interest from healthcare providers and insurers focused on cost-effective diabetes prevention strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03194009

Status

UNKNOWN

Phase

Not Applicable (NA)

Sponsor

Instituto Nacional de Salud Publica, Mexico

Executive brief

Investment-Ready Snapshot

The PRuDENTE initiative, sponsored by the Instituto Nacional de Salud Publica in Mexico, aims to evaluate the cost-effectiveness of metformin combined with lifestyle modifications in preventing type 2 diabetes among pre-diabetic adults with obesity. Given the high prevalence of diabetes in Mexico, this study addresses a significant public health challenge and has the potential to inform national healthcare policies. If successful, the findings could lead to broader adoption of metformin as a preventive measure, impacting the pharmaceutical market for diabetes medications and lifestyle interventions. The study's outcomes may also attract interest from healthcare providers and insurers focused on cost-effective diabetes prevention strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 07, 2018
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03194009

Indication

Diabetes Mellitus, Type 2

Modality

small molecule

Target

Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Intervention

Metformin, Lifestyle intervention

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.